BMS completes Inhibitex deal

by Admin 14. February 2012 13:15

 Bristol-Myers Squibb has completed its $2.5 billion cash acquisition of biopharmaceutical company Inhibitex, Inc.

The deal includes Inhibitex’s lead compound nucleotide polymerase (NS5B) inhibitor INX-189 for the treatment of chronic hepatitis C and continues BMS’ approach to drug development.

Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb, said the deal “represents an important investment in the long-term growth of the company” when it was first announced last month.

The company’s ‘string of pearls’ strategy has seen it merge, partner or acquire a host of companies focusing on products in its core therapeutic areas since 2007.

Nucleotide polymerase (NS5B) inhibitor INX-189 is currently in Phase II trials in combination with pegylated interferon and ribavirin for chronic hepatitis C.

Analysts have predicted pharma companies will receive billion dollar sales for a number of hepatitis C therapies currently in development. The industry has also been given a much needed boost recently by the approval of new oral therapies including Merck & Co’s Victrelis (boceprevir) and J&J, Vertex Pharmaceuticals and Mitsubishi Tanabe’s Incivek/Incivo (telaprevir).

In December 2011, BMS entered into an alliance with Johnson & Johnson’s Tibotec for the development of an all-oral combination therapy based on BMS’ daclatasvir and Tibotec’s NS3 protease inhibitor TMC435. Phase II trials of the combination are planned to start later this year.

Comments are closed


Tag cloud


<<  April 2018  >>

View posts in large calendar

Month List